Stem cell therapy could have great potential for the treatment of a wide variety of diseases. Stem cells might have the ability to differentiate into a widespread cell types, and to repopulate and revitalize the damaged cells with healthy tissue, and improve its performance. We provide here the evidence supporting the critical use of stem cell as a treatment in disease conditions existing with high glucose complaint such as diabetes. The reduction of glucose stimulated cell proliferation and high glucose enhanced apoptosis in rat model, which may be a problem in therapeutic strategies based on ex vivo expansion of stem cell, and may also propagate the development of osteoporosis in high glucose complaint such as diabetes. This leads to the hypothesis that, high glucose could be more deleterious to stem cell therapy that may be due to the aggravation of oxidative stress triggered by high glucose. These findings may help to understand the possible reasons associated with high glucose induced detrimental effects on stem cells as well as provide novel therapeutic strategies for preventing the adverse effects of glucose on the development and progression of stem cells in patients with diabetes.
INTRODUCTION
Stem cell therapy could have great potential for the treatment of a wide variety of diseases. 1 Stem cells might have the ability to differentiate into a widespread cell types, and to repopulate and revitalize the damaged cells with healthy tissue, and improve its performance. 2 Stem cells are also expand and differentiate to different cell entities for regenerative therapies by applying culture media of different compositions. 3 Common media contain diverse elements such as glucose to ensure the stable maintenance of cell differentiation after prolonged culture in vitro. The applied culture media components may influence stem cell proliferation, replicative senescence, and apoptosis. 4 Glucose is an essential source of cellular energy and is an important substrate for protein and lipid synthesis. Glucose enters eukaryotic cells through two different membrane associated carrier proteins, glucose transporter facilitators (GLUT) and the Na + -coupled glucose transporters (SGLT). 5 Glucotoxicity or high glucose concentrations may impair β-cell function and finally induce apoptosis. 6 Elevated glucose concentrations affect pancreatic β-cells and can lead to oxidative damage in the major organs in the body, such as eyes, kidneys, nerves, and blood vessels. 7 In stem cell obtained from rats high glucose induced cellular senescence, while
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International Journal of Hematology Oncology and Stem Cell Research ijhoscr.tums.ac.ir reduction of glucose enhanced proliferation, decreased apoptosis, and increased the number of colony forming units. 8, 9 We provide here the evidence supporting the critical use of stem cell therapy in the disease conditions existing with high glucose complaint such as diabetes. This leads to the hypothesis that, high glucose could be more deleterious to stem cell therapy that may be due to the aggravation of oxidative stress triggered by high glucose.
Evidences Experimental Evidence
Reducing glucose stimulated cell proliferation and high glucose enhanced apoptosis in rat model, 8 which may be a problem in the stem cells-based therapeutic strategies, 10 and may also propagate developing osteoporosis in high glucose conditions such as diabetes. 11 Some but not all studies suggested that β-cell mass is significantly reduced in diabetic patients and thus increased apoptosis. [12] [13] [14] Both human and animal studies have found that increasing of β-cell apoptosis is an important reason of insulin deficiency in type 2 diabetic patients. 15, 16 So far, several lines of evidence have suggested that chronic persistent hyperglycemia results in β-cells dysfunction and ultimately apoptosis, called β-cell glucotoxicity. 17 Diabetes is associated with reduced numbers and functional viability of stem cells in vivo, which lead to degenerative pathologies of the musculoskeletal system. Stolzing et al., elucidated the effects of elevated glucose levels on the proliferation of bone marrow mesenchymal stem cells, and found that culture in high-glucose-containing medium had a negative effect on the colony formation and differentiation. 18 Human adipose-derived mesenchymal stem cells may be ideal source of cells for musculoskeletal system regeneration, but the harsh chemical microenvironment may significantly influence the biological and metabolic vitality of this stem cell and impair their repair potential. Liang et al. harvested and cultured Human adipose-derived mesenchymal stem cells under low glucose condition for two weeks, and reported that low glucose is a positive factor that affects the survival and biological behaviors of such stem cells. 19 Elseberg et al., compared high-with low-glucose medium showing that high-glucose has positive effects on stem cell proliferation. 20 Kim et al., identified miR-486-5p, which is progressively expressed in human adipose tissue-derived mesenchymal stem cells, and showed that high glucose increases miR-486-5p expression. 21 Bone marrow-derived mesenchymal stem cells have multilineage differentiation potential and can be designated for the treatment of diabetic patients. Though, high-glucose levels can adversely affect the function of stem cells and justifies the need for a strategy to overcome this problem. Khan et al., showed that growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells in animal model. 22 Elevated glucose concentrations may harm function of the cells and induce apoptosis. Li et al., assessed the effects of high glucose concentrations on human mesenchymal stem cells in vitroand reported that proliferation and osteogenic differentiation are stimulated by high glucose. 23 Keats and Khan, investigated whether stem cells show cellular activation and dysfunction to high-glucose levels, and showed that though endothelial progenitor cells are resistant to high-glucose levels, but highglucose levels may cause reduced growth and altering the differentiation potential. 24 Although low glucose concentration (5.5mM) is physiologically maintained in vivo, high glucose levels (25mM) induced forming embryoid body, which is an important step in the differentiation of pluripotent stem cells, in vitro. Mochizuk et al., investigated the effect of glucose concentration during stem cells embryoid body formation, and showed that lowglucose concentration was suitable. 25 Howard et al., investigated whether diabetes induces a repair defect in skeletal muscle myocytes, and showed that this repair defect was mimicked in cultured cells by prolonged exposure to high-glucose. 26 Kim et al., examined the effects of high-glucose on stem cell proliferation, and concluded that high-glucose levels can increase the rate of stem cells growth. 27 
Clinical Evidence
In a group of metabolic diseases in which a person experienced high-glucose condition either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced by the pancreas, high-glucose produces three big diabetes signs including polyuria, polydipsia and polyphagia. 28 High-glucose levels also can lead to severe complications such as vision loss, cardiovascular diseases, kidney disorder, and nerve damage . [29] [30] [31] [32] [33] Clinical studies have shown that high-glucose level leads to endothelial cell dysfunction in diabetes (Table 1) . [34] [35] [36] Stem cells offer the greatest potential for developing an abundant source of pancreatic islets, hence Insulin-producing cells for transplantation can be generated from both embryonic and adult stem cells. 37 Phadnis et al., isolated stem cells from diabetic patients, to investigate the effect of diabetic microenvironment on human bone marrow-derived mesenchymal stem cells, and claimed that diabetic high-glucose level plays a major role in inducing the differentiation of human stem cells. 38 Gu et al., enrolled type 1 diabetes patients, and harvested hematopoietic stem cells. 39 They showed that hematopoietic stem cells to be an effective long-term treatment for insulin dependence that achieved a greater efficacy in patients without diabetic ketoacidosis at diagnosis. Fadini et al., explored whether circulating pericyte progenitor cells levels are affected by glucose control in a poorly controlled type 2 diabetic patients. 40 They concluded that glucose control transiently mobilizes PPCs diabetic patients with micro angiopathy. Increase in pericyte progenitor cells may represent a vasoregenerative event or may be a consequence of ameliorated glucose control on microvascular lesions. Li et al., examined the impact of autologous hematopoietic stem cell transplantation on lymphocytes and pancreatic β-cell function, in thirteen patients with new onset of type 1 diabetes. 41 They reported that autologous hematopoietic stem cell transplantation modulated lymphocytes and preserved β-cell function in Chinese patients with new onset of type 1 diabetes and diabetic ketoacidosis. Ruiz-Salmeron et al., compared the neovasculogenesis and clinical improvement of diabetic patients with peripheral artery disease, at baseline and at 3 and 12 months after autologous bone marrow-derived stem cell transplantation. They reported that in diabetic patients with critical limb ischemia, autologous bone marrow-derived stem cell transplantation is a safe procedure that generates a significant increase in the vascular network in ischemic areas and promotes remarkable clinical improvement. 42 Zhao et al., developed a procedure for stem cell therapy in which a patient's blood is circulated through a closed-loop system that separates lymphocytes from the whole blood and briefly co-cultures them with adherent in 15 patients with type 1 diabetes. 43 They concluded that stem cell therapy is safe, and in individuals with moderate or severe type 1 diabetes, a single treatment produces lasting improvement in metabolic control. Jiang 44 This pilot clinical trial indicates that transplantation of stem cells represents a simple, safe and effective therapeutic approach for type 2 diabetes patients with islet cell dysfunction. Bhansali et al., studied the efficacy of autologous bone marrow-derived stem cell transplantation in ten patients with type 2 diabetes for more than 5 years, failure of triple oral anti-diabetic drugs, currently on insulin at least for one year, and glutamic acid decarboxylase antibody negative. 45 Their observations indicated that stem cells therapy is a safe and effective modality of treatment to improve beta-cell function in patients with type 2 diabetes.
DISCUSSION
Stem cells are defined as cells that have clonogenic and self-renewing capabilities and differentiate into multiple cell lineages. Stem cells therapy offers the greatest potential for developing an abundant source of pancreatic islets. Insulinproducing cells for transplantation can be generated from both embryonic and adult stem cells. Before stem cell therapeutic strategies for diabetes mellitus can be transferred to clinical application in humans, stem cell biologists have to address several pressing issues related to appropriate differentiation protocols, functional aspects of insulin secretion, its regulation, cellmaturation and control of proliferation, with ethical norms and safety. Not only blood glucose control is the most important target in managing patients with diabetes, but also high glucose may lead to several adverse effects in such patients and subsequent stem cell therapy. [46] [47] [48] [49] [50] Line of evidences showed that diabetes is now curable by transplantation therapy, and stem cells offer a potential starting material from which to generate the large numbers of cells required. 51, 52 While some argue, the generation of the large numbers of cells by stem cell therapy such as perfect beta-cell may not necessarily lead to the most suitable tissue for transplantation in patients with diabetes. 53 It is also possible that stem cellderived insulin-producing cell clusters within these experiments are more efficient at producing insulin than conventionally isolated islets, based on the cells in vitro high-glucose environment. Accordingly, Fujikawa et al., characterized embryonic stem cellderived insulin-expressing cells and assessed their relevance for treating type I diabetes, the clusters in their system may be applied to the marginal mass transplant theory. 54 Long and relatively high-glucose levels in the culture media may have stimulated a greater insulin response than would be expected from normal islet cells. However, the risk of teratoma formation would need to be eliminated before embryonic stem cell-based therapies for treating diabetes are considered. Unexpectedly, Keats and Khan found the progenitor population most affected by high glucose is the mesenchymal cell type. When they cultured bone marrow-derived progenitor cells in high glucose media, and noted a significant reduction in cell numbers at day one. Besides, this effect was normalized upon continued exposure. 24 Other recent study found that in vitro stimulation with advanced glycation products induced generation of reactive oxygen species, and inhibited dose-dependently proliferation and migration of mesenchymal stem cells. 55 Furthermore, recent work has shown that exposure of vascular smooth muscle cells to high glucose activates several signal transduction networks responsible for mediating the proliferative and growth-promoting response in patients with diabetes. 56 The adverse effects of high glucose on stem cell therapy have been suggested through different mechanisms include, induces adipogenic differentiation of muscle-derived stem cells, 50 has an effect in stimulating mouse embryonic stem cell proliferation through the Ca 2+ /PKC, MAPKs, and the AT1 receptor, 49 insulin and estradiol are able to contain the deleterious effect of high glucose on stem cells-derived osteoblast proliferation and function, 48 increase cell cycle regulatory proteins of mouse embryonic stem cells by PI3-K/Akt and MAPKs signal pathways, 27 and increases the expression of Cbfa1, BMP-2 and bone matrix protein and enhances the calcification of vascular smooth muscle cells (Figure 1 ). 56 International Journal of Hematology Oncology and Stem Cell Research ijhoscr.tums.ac.ir Although the protection and expansion of all forms of stem cell therapy, which offer great hope for a cure and better treatments for patients who suffered from diabetes, but better understand high glucose pathogenesis could prevent the treatment or improve the survival, and ultimately to expand therapeutics. These findings may help to understand the possible reasons associated with high glucose induced detrimental effects on stem cells as wellas provide novel therapeutic strategies for preventing the adverse effects of glucose on the development and progression of stem cells in patients with diabetes.
